Clinical trials: Flu
Immunization
FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV
In 2013 the UK government introduced the nasal flu spray vaccine (Fluenz Tetra®) for use in children from 24 months to less than 18 years of age.
- Trial name
- NCT04222595
- Testing
- Fluenz Tetra nasal spray suspension
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Influenza
Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations
The purpose of this study is to show the non-inferiority of different formulations of GlaxoSmithKline Biologicials' influenza vaccine.
- Trial name
- NCT00633074
- Testing
- Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A), Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)
- Where
- 3 sites in Estonia
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pregnancy
Vaccine Acceptance in Pregnant Minority Women
The purpose of study will be to test two vaccine education strategies to learn how they impact flu and pertussis (Tdap) vaccination rates and attitudes regarding vaccination during pregnancy after participating in the…
- Trial name
- NCT01740310
- Testing
- Maternal Vaccine Education
- Where
- 4 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Emory University
Influenza
Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older
The purpose of this study is to comply with the post marketing condition to the exceptional approval of Arepanrix™ in Japan and to assess the immunogenicity and safety of GSK Biologicals' H1N1 influenza vaccine healthy Japanese…
- Trial name
- NCT01114620
- Testing
- Arepanrix™
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, COVID-19
Dime La VerDAD: Verify, Debunk, and Disseminate
Dime la Verdad (Tell me the truth) will evaluate the use of storytelling by community health workers as a communication strategy to disseminate reliable health information on social media and encourage informed decision-making in…
- Conditions
- Influenza, COVID-19, Communication Research, Health Behavior
- Trial name
- NCT06417762
- Testing
- Science Communication Curriculum Cohort 1, Science communication curriculum Cohort 2, Science communication curriculum Cohort 3
- Where
- 4 sites in United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Chicago
COVID-19, Influenza A
MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study
The purpose of this study is to evaluate the usability of the MGC Health COVID-19 \& Flu A+B Home Multi Test in home use.
- Conditions
- COVID-19, Influenza A, Influenza B
- Trial name
- NCT05732610
- Testing
- MGC Health COVID-19 & Flu A+B Home Multi Test, MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Medical Group Care, LLC
Influenza
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
The primary objectives of this study were: To describe the immunogenicity of the 2018-2019 formulation of Fluzone® Quadrivalent vaccine in children 6 to less than (<) 36 months of age and 3 to <9 years of age, and in adults 18 to…
- Trial name
- GRC90 (NCT03617523)
- Testing
- Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
- Where
- 3 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children
The purpose of this study is to compare two influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and safety with a six month follow-up after first vaccination.
- Trial name
- NCT00383123
- Testing
- Fluarix™, Fluzone
- Where
- 40 sites in United States
- Volunteers
- 3,327 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults
The purpose of this study were to obtain additional evidence in support of the safety and immunogenicity of a recombinant hemagglutinin (rHA) vaccine in an elderly population, and to establish non-inferiority of the…
- Trial name
- NCT00395174
- Testing
- Influenza Vaccination
- Where
- 7 sites in United States
- Volunteers
- 870 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza Vaccine
Preliminary Safety Assessment of a Quadrivalent Subunit Influenza Vaccine in China
This study evaluates the safety of the quadrivalent subunit influenza vaccine in individuals aged 3 years and older in Jiangsu Province, China.
- Trial name
- NCT07710586
- Testing
- quadrivalent subunit influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 3,105 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
Influenza, Human
Intramuscular CodaVax-H1N1 in Healthy Adults
This study is a Phase 1, 2-part, randomised, double-blind, controlled, clinical trial to evaluate the safety and immune response of CodaVax-H1N1 in healthy adults aged 18 to 49 years.
- Trial name
- NCT05223179
- Testing
- CODA-VAX H1N1, Flucelvax Quad, Saline
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
Upper Respiratory Tract Infections
Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu
The aim of the study is to see if lozenges containing a low dose of interferon-alpha can prevent and/or reduce the severity of colds and flu.
- Trial name
- NCT00895947
- Testing
- interferon-alpha
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Influenza
pH1N1 Blinded Challenge Study
This protocol describes a clinical trial to develop and validate a Controlled Human Infection Model (CHIM) for influenza A/Arkansas/08/2020 (pH1N1).
- Trial name
- NCT07110532
- Testing
- A/Arkansas/08/2020 (pH1N1)
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine
A phase 3 study to obtain additional safety and immunogenicity data on Solvay's cell-derived seasonal trivalent subunit influenza vaccine in adult and elderly subjects without significant illnesses and to demonstrate consistency…
- Trial name
- NCT00999206
- Testing
- Influenza Vaccine
- Where
- 19 sites in Australia, New Zealand
- Volunteers
- 3,138 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia
- Trial name
- NCT05079152
- Testing
- COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,404 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Novel Influenza A (H1N1), A New Flu Virus of Swine Origin
Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine
This is an observational study of safety and occurrence of influenza-like illness following administration of flu cell culture derived adjuvanted swine origin A (H1N1) pandemic subunit vaccine in subjects 6 months of age and…
- Trial name
- NCT01037855
- Testing
- Non-intervention observational study
- Where
- 10 sites in Chile, Colombia and 2 more
- Volunteers
- 4,028 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Kidney Transplant
Cell-mediated Immune Response to Influenza Vaccine
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for organ transplant patients, studies have shown…
- Trial name
- NCT00677547
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Influenza
Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults
The study is designed to assess the immunogenicity and safety of one booster vaccination with 45 μg of a recombinant H5N1 influenza (A/Indonesia/05/2005) HA vaccine in healthy young adults, previously primed with a…
- Trial name
- NCT01195038
- Testing
- Recombinant Influenza HA Vaccine (H5N1)
- Where
- 2 sites in Japan
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Influenza
The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.
Comparative assessment of the tolerability, safety and immunogenicity of the Flu-M vaccine vs. the Ultrix® vaccine by single vaccination of children aged 6 to 17 years.
- Trial name
- NCT05317767
- Testing
- Flu-M [Inactivated split influenza vaccine], Inactivated Split Influenza Vaccine
- Where
- 2 sites in Russia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Influenza
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this Phase 3, observer-blind, placebo-controlled, multi-center study is to characterize the immunogenicity \& safety of the investigation vaccination regimen of GSK 1557484A vaccine given to adults aged ≥18 years.
- Trial name
- NCT00616928
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- 40 sites in United States, Canada
- Volunteers
- 4,561 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.